research use only

Belinostat (PXD101) HDAC inhibitor

Name: Belinostat (PXD101)
Brand: Selleck Chemicals
SKU: S1085
Availability: InStock
Rating: 5 (104 reviews)

Cat.No.S1085

Belinostat is a novel HDAC inhibitor with IC50 of 27 nM in a cell-free assay, with activity demonstrated in cisplatin-resistant tumors. Belinostat (PXD101) induces autophagy.

Chemical Structure

Molecular Weight: 318.35

Jump to

Quality Control

Batch: Purity: 99.74%

99.74

Related Targets	JAK BET Histone Methyltransferase PKC PARP HIF PRMT EZH2 AMPK Histone Acetyltransferase
Other HDAC Products	Entinostat (MS-275) Trichostatin A (TSA) RGFP966 Tubastatin A Quisinostat (JNJ-26481585) Dihydrochloride Tubastatin A HCl Fimepinostat (CUDC-907) Givinostat (ITF-2357) Hydrochloride Monohydrate Mocetinostat (MGCD0103) Ricolinostat (ACY-1215)

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT116	Function Assay	0.9 μM	24 h		down-regulats TS protein levels after 6 h incubation	17124594
HCT116	Growth Inhibition Assay		48 h		EC50=0.28 μM	17124594
Granta-519	Growth Inhibition Assay		24 h		IC50=56.3 μM	20068080
Jeko-1	Growth Inhibition Assay		24 h		IC50=0.2 μM	20068080
HBL-2	Growth Inhibition Assay		24 h		IC50=0.4 μM	20068080
Panc-1	Apoptosis Assay	100/500/1000 nM	48 h		induces dose dependent apoptosis	22681698
AsPC-1	Apoptosis Assay	100/500/1000 nM	48 h		induces dose dependent apoptosis	22681698
T3M4	Apoptosis Assay	100/500/1000 nM	48 h		induces dose dependent apoptosis	22681698
Panc-1	Growth Inhibition Assay	0-800 nM	48 h		inhibits cell proliferation in a dose dependent manner	22681698
AsPC-1	Growth Inhibition Assay	0-800 nM	48 h		inhibits cell proliferation in a dose dependent manner	22681698
T3M4	Growth Inhibition Assay	0-800 nM	48 h		inhibits cell proliferation in a dose dependent manner	22681698
MiaPaCa2	Function Assay	1/10 μM	24 h		induces growth arrested in G2/M	23475695
AsPc1	Function Assay	1/10 μM	24 h		induces growth arrested in G2/M	23475695
Panc0403	Apoptosis Assay	1 μM	24 h		induces apoptosis	23475695
Panc1005	Apoptosis Assay	1 μM	24 h		induces apoptosis	23475695
Panc0327	Apoptosis Assay	1 μM	24 h		induces apoptosis	23475695
Panc0203	Growth Inhibition Assay		48 h		EC50=22.2 μM	23475695
PL45	Growth Inhibition Assay		48 h		EC50=20.8 μM	23475695
Panc1005	Growth Inhibition Assay		48 h		EC50=1.1 μM	23475695
Panc0403	Growth Inhibition Assay		48 h		EC50=1.1 μM	23475695
BxPc3	Growth Inhibition Assay		48 h		EC50=1.0 μM	23475695
MiaPaCa2	Growth Inhibition Assay		48 h		EC50=0.7 μM	23475695
Panc0327	Growth Inhibition Assay		48 h		EC50=0.5 μM	23475695
AsPc1	Growth Inhibition Assay		48 h		EC50=0.3 μM	23475695
PC9	Function Assay	0.5/1/2 μM	4 h	DMSO	inhibits the levels of Akt (p-Akt) and EGFR	23515752
H1650	Function Assay	0.5/1/2 μM	4 h	DMSO	inhibits the levels of Akt (p-Akt) and EGFR	23515752
H460	Function Assay	0.5/1/2 μM	4 h	DMSO	inhibits the levels of Akt (p-Akt) and EGFR	23515752
PC9	Function Assay	500 nM	24 h	DMSO	decreases EGFR expression	23515752
H1650	Function Assay	500 nM	24 h	DMSO	decreases EGFR expression	23515752
H460	Function Assay	500 nM	24 h	DMSO	decreases EGFR expression	23515752
HCC4006	Growth Inhibition Assay		72 h	DMSO	IC50=0.46 μM	23515752
HCC2935	Growth Inhibition Assay		72 h	DMSO	IC50=0.97 μM	23515752
HCC827	Growth Inhibition Assay		72 h	DMSO	IC50=0.29 μM	23515752
HCC2279	Growth Inhibition Assay		72 h	DMSO	IC50=0.4 μM	23515752
PC9	Growth Inhibition Assay		72 h	DMSO	IC50=0.29 μM	23515752
H820	Growth Inhibition Assay		72 h	DMSO	IC50=0.4 μM	23515752
H1650	Growth Inhibition Assay		72 h	DMSO	IC50=0.88 μM	23515752
H1975	Growth Inhibition Assay		72 h	DMSO	IC50=0.68 μM	23515752
H520	Growth Inhibition Assay		72 h	DMSO	IC50=0.75 μM	23515752
H1299	Growth Inhibition Assay		72 h	DMSO	IC50=1.2 μM	23515752
H460	Growth Inhibition Assay		72 h	DMSO	IC50=0.86 μM	23515752
H1666	Growth Inhibition Assay		72 h	DMSO	IC50>10 μM	23515752
PANC-1	Function Assay	10 μM	2/4 h	DMSO	increases intracellular ROS level	23743198
PANC-1	Cell Viability Assay	1/10 μM	48 h	DMSO	decreases cell viability in a dose dependent manner	23743198
PANC-1	Function Assay	10 μM	2/4/6 h	DMSO	induces AMPK activation	23743198
HL-60	Function Assay	0.2 μM	24/48/72 h		enhances RA-induced granulocytic differentiation	25864732
NB4	Function Assay	0.2 μM	24/48/72 h		enhances RA-induced granulocytic differentiation	25864732
HL-60	Function Assay	2 μM	24/48 h		blocks cell cycle in S phase	25864732
NB4	Function Assay	2 μM	24/48 h		blocks cell cycle in S phase	25864732
HL-60	Cell Viability Assay	0.2/2 μM	24/48/72 h		decreases cell viability in both time and dose dependent manner	25864732
NB4	Cell Viability Assay	0.2/2 μM	24/48/72 h		decreases cell viability in both time and dose dependent manner	25864732
RAW264.7	Anti-inflammatory assay		1 hr		Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as suppression of IL6 production pre-incubated for 1 hr before LPS stimulation for 24 hrs by ELISA method, IC50 = 0.000059 μM.	25113875
HEK293	Function assay				Inhibition of HDAC6 in HEK293 cells, IC50 = 0.015 μM.	18308563
HEK293	Function assay				Inhibition of HDAC1 in HEK293 cells, IC50 = 0.018 μM.	18308563
HeLa	Function assay		30 mins		Inhibition of HDAC in human HeLa cells nuclear extracts incubated for 30 mins by fluorescent assay, IC50 = 0.0264 μM.	25113875
HeLa	Function assay				Inhibition of HDAC in human HeLa cells using Fluor de Lys as substrate by fluorescence assay, IC50 = 0.027 μM.	23639537
HeLa	Function assay				Inhibition of HDAC from human HeLa cells, IC50 = 0.028 μM.	18247554
HEK293	Function assay				Inhibition of HDAC3 in HEK293 cells, IC50 = 0.046 μM.	18308563
MDA-MB-231	Antiproliferative assay		72 hrs		Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by resazurin dye based fluorescence assay, IC50 = 0.062 μM.	29456804
Jurkat	Antiproliferative assay		48 hrs		Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay, IC50 = 0.07 μM.	29533873
A549	Antiproliferative assay		72 hrs		Antiproliferative activity against human A549 cells after 72 hrs by resazurin dye based fluorescence assay, IC50 = 0.077 μM.	29456804
HeLa	Antiproliferative assay		72 hrs		Antiproliferative activity against human HeLa cells after 72 hrs by resazurin dye based fluorescence assay, IC50 = 0.087 μM.	29456804
MCF7	Antiproliferative assay		72 hrs		Antiproliferative activity against human MCF7 cells after 72 hrs by resazurin dye based fluorescence assay, IC50 = 0.096 μM.	29456804
HEL	Antiproliferative assay		48 hrs		Antiproliferative activity against human HEL cells after 48 hrs by MTT assay, IC50 = 0.1 μM.	29533873
Huh7	Antiviral assay		3 days		Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by luciferase reporter gene assay, EC50 = 0.12 μM.	25490700
HCT116	Antiproliferative assay		48 hrs		Antiproliferative activity against human HCT116 cells after 48 hrs by SRB assay, GI50 = 0.13 μM.	27344487
MOLT4	Antiproliferative assay		48 hrs		Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay, IC50 = 0.14 μM.	29533873
HCT116	Antiproliferative assay				Antiproliferative activity against human HCT116 cells assessed as growth inhibition, IC50 = 0.16 μM.	21650221
HCT116	Antiproliferative assay				Antiproliferative activity against human HCT116 cells, IC50 = 0.16 μM.	21742496
SK-N-BE(2)	Antiproliferative assay		48 hrs		Antiproliferative activity against human SK-N-BE(2) cells after 48 hrs by MTT assay, IC50 = 0.31 μM.	29533873
PC3	Antiproliferative assay		48 hrs		Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay, GI50 = 0.39 μM.	27344487
PC3	Antiproliferative assay		96 hrs		Antiproliferative activity against human PC3 cells after 96 hrs by celltiter 96 assay, IC50 = 0.45 μM.	21634430
H1299	Antiproliferative assay				Antiproliferative activity against human H1299 cells, IC50 = 0.46 μM.	21650221
HeLa	Antiproliferative assay		48 hrs		Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay, IC50 = 0.51 μM.	29533873
HCT116	Antiproliferative assay		96 hrs		Antiproliferative activity against human HCT116 cells after 96 hrs by celltiter 96 assay, IC50 = 0.6 μM.	21634430
A2780	Antiproliferative assay		96 hrs		Antiproliferative activity against human A2780 cells after 96 hrs by celltiter 96 assay, IC50 = 0.67 μM.	21634430
HuH7	Cytotoxicity assay		3 days		Cytotoxicity against human HuH7 cells assessed as inhibition of cell viability after 3 days by CellTiter 96 assay, CC50 = 0.68 μM.	25490700
COLO205	Antiproliferative assay		96 hrs		Antiproliferative activity against human COLO205 cells after 96 hrs by celltiter 96 assay, IC50 = 0.7 μM.	21634430
A549	Antiproliferative assay		48 hrs		Antiproliferative activity against human A549 cells after 48 hrs by SRB assay, GI50 = 0.78 μM.	27344487
HL60	Antiproliferative assay		48 hrs		Antiproliferative activity against human HL60 cells after 48 hrs by SRB assay, GI50 = 1.09 μM.	27344487
K562	Antiproliferative assay		48 hrs		Antiproliferative activity against human K562 cells after 48 hrs by MTT assay, IC50 = 1.1 μM.	29533873
PC3	Antiproliferative assay		48 hrs		Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay, IC50 = 1.3 μM.	29533873
NFF	Cytotoxicity assay		72 hrs		Cytotoxicity against human NFF cells after 72 hrs by SRB assay, IC50 = 1.4 μM.	28241112
HEK293	Cytotoxicity assay		48 hrs		Cytotoxicity against HEK293 cells after 48 hrs by resazurin assay, IC50 = 1.4 μM.	28241112
NFF	Cytotoxicity assay		72 hrs		Cytotoxicity against human NFF cells after 72 hrs by sulforhodamine B assay, IC50 = 1.42 μM.	30245402
HEK293	Cytotoxicity assay		48 hrs		Cytotoxicity against HEK293 cells after 48 hrs by resazurin dye based assay, IC50 = 1.42 μM.	30245402
RAW264.7	Anti-inflammatory assay		1 hr		Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as suppression of nitric oxide production pre-incubated for 1 hr before LPS stimulation for 24 hrs by Griess reagent based assay, IC50 = 2.2 μM.	25113875
RAW264.7	Anti-inflammatory assay		1 hr		Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as suppression of TNFalpha production pre-incubated for 1 hr before LPS stimulation for 24 hrs by ELISA method, IC50 = 4.7 μM.	25113875
RAW264.7	Anti-inflammatory assay		1 hr		Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as suppression of PGE2 production pre-incubated for 1 hr before LPS stimulation for 24 hrs by enzyme immunoassay method, IC50 = 8.28 μM.	25113875
Huh-luc/neo7	Function assay	1 uM	1 to 3 hrs		Inhibition of HDAC class 1 in human Huh-luc/neo7 cells assessed as histone H3 acetylation at 1 uM after 1 to 3 hrs by Western blotting analysis	25937017
PC3	Function assay	0.3 uM	48 hrs		Inhibition of HDAC in human PC3 cells assessed as increase in amount of acetylated histone H3 at 0.3 uM after 48 hrs by Western blot analysis	27344487
HCT116	Function assay	0.3 uM	48 hrs		Inhibition of HDAC in human HCT116 cells assessed as increase in amount of acetylated histone H3 at 0.3 uM after 48 hrs by Western blot analysis	27344487
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 64 mg/mL (201.03 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.000mg/ml (12.56mM)	Taking the 1 mL working solution as an example, add 50 μL of 80 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.000mg/ml (3.14mM)	Taking the 1 mL working solution as an example, add 50 μL of 20 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	318.35	Formula	C₁₅H₁₄N₂O₄S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	866323-14-0	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	PXD101,NSC726630, PX-105684			Smiles	C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO

Mechanism of Action

Features	Lead compound of Topotarget.
Targets/IC₅₀/Ki	HDAC (Cell-free assay) 27 nM
In vitro	Belinostat inhibits the growth of tumor cells (A2780, HCT116, HT29, WIL, CALU-3, MCF7, PC3 and HS852) with IC50 from 0.2-0.66 μM. PD101 shows low activity in A2780/cp70 and 2780AD cells, which are cisplatin and doxorubicin-resistant derivatives of A2780 cells. This compound could induce apoptosis through PARP cleavage and acetylation of histones H3/H4. It inhibits bladder cancer cell growth, especially in 5637 cells, which shows accumulation of G0-G1 phase, decrease in S phase and increase in G2-M phase. The growth inhibitory activity of this chemical on cell lines is not strongly influenced by the multidrug-resistant phenotype, whereas the activity of docetaxel is clearly affected. It could enhance the growth inhibitory activity of docetaxel or carboplatin in OVCAR-3 and A2780 cells. This compound also shows enhanced tubulin acetylation in ovarian cancer cell lines. A recent study shows that it activates protein kinase A in a TGF-β signaling-dependent mechanism and decreases survivin mRNA.
Kinase Assay	Histone Deacetylase Activity
Kinase Assay	Subconfluent cultures are harvested and washed twice in ice cold PBS and pelleted by centrifugation at 200 × g for 5 min. The cell pellet is resuspended in two volumes of lysis buffer [60 mM Tris buffer (pH 7.4) containing 30% glycerol and 450 mM NaCl] and lysed by three freeze (dry ice) thaw (30 °C water bath) cycles. Cell debris is removed by centrifugation at 1.2 × 10⁴ g for 5 min, and the supernatant is stored at −80 °C. Histone H4 peptide (sequence SGRGKGGKGLGKGGAKRHRK corresponding to the 20 NH2-terminal residues) is acetylated by a recombinant protein containing the hypoxanthine-aminopterin-thymidine domain of p300, using [³H]acetyl CoA as a source of acetate. H4 peptide (100 μg) is mixed with hypoxanthine-aminopterin-thymidine buffer (50 mM Tris HCl pH 8.0, 5% glycerol, 50 mM KCl, and 0.1 mM EDTA), 1 mM DTT, 1 mM 4-(2-aminoethyl) benzenesulfonylfluoride, 1 × complete protease inhibitors, 50 μL of purified p300, and 1.85 m [³H]acetyl CoA (4.50Ci/mmol) in a final volume of 300 μL and incubated at 30 °C for 45 min. The p300 protein is removed by incubation with 20 μL of 50% Ni-agaroase beads for 1 hour at 4 °C and centrifugation. The supernatant is applied to a 2 mL Sephadex G15 column, and the flow through is collected. One milliliter of distilled H₂O is gently applied, and three drop fractions are collected; this is repeated until 4–5 mL of distilled H₂O has been added, and ∼40 fractions are collected. Three microliters of each fraction are diluted in 2 mL of scintillation fluid and counted in a scintillation counter to identify the fractions containing the labeled peptide. These fractions are pooled, and 1 μL of the combined sample is measured to assess the radioactivity in every peptide batch (3-7×10³ cpm/μL). For activity assays, the reaction is carried out in a total volume of 150 μL of buffer [60 mM Tris (pH 7.4) containing 30% glycerol] containing 2 μL of cell extract and, where used, 2 μL of this compound. The reaction is started by the addition of 2 μL of [³H] labeled substrate (acetylated histone H4 peptide corresponding to the 20 NH₂-terminal residues). Samples are incubated at 37 °C for 45 min, and the reaction stopped by the addition of HCl and acetic acid (0.72 and 0.12 M final concentrations, respectively). Released [³H]acetate is extracted into 750 μL of ethyl acetate, and samples are centrifuged at 1.2× 10⁴ g for 5 min. The upper phase (600 μL) is transferred to 3 mL of scintillation fluid and counted.
In vivo	Belinostat indicates significant tumor growth delay in A2780 and A2780/cp70 xenograft at a dose of 10mg/kg with no effects on the body weight. This compound also induces p21WAF1, HDAC core and cell communication genes in mouse bladder tumors. Its monotherapy induces dose-proportional antitumor effects with TGI of 47% at a dose of 100mg/kg in A2780 xenograft. The combination of this chemical (100 mg/kg) with carboplatin (40 mg/kg) could delay tumor growth from 18.6 days to 22.5 days. Combining with bortezomib, it results in great tumor inhibition and gastrointestinal toxicity in mice with bortezomib-resistant UMSCC-11A xenograft.
References	[1] https://pubmed.ncbi.nlm.nih.gov/12939461/ [2] https://pubmed.ncbi.nlm.nih.gov/17935615/ [3] https://pubmed.ncbi.nlm.nih.gov/16928830/ [4] https://pubmed.ncbi.nlm.nih.gov/21757750/ [5] https://pubmed.ncbi.nlm.nih.gov/17237265/

Applications

Methods	Biomarkers	Images	PMID
Western blot	p-H2AX(Ser139) / KU70 / KU80 / RAD51 / RAD52 / ERCC1 Acetyl Histone H3 / Acetyl Histone H4 / Acetyl tubulin p21 / p27 SOS1 / SOS2 PARP / p-ERK / p-p38 / p38 / p-BRAF / p-MEK / MEK		24155971
Growth inhibition assay	Cell viability IC50		24155971

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06406465	Not yet recruiting	Carcinoma Neuroendocrine\|Tumor Neuroendocrine\|Tumors Neuroendocrine\|Neuroendocrine; Carcinoma\|Small Cell; Receptors	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	May 15 2024	Phase 2
NCT04315233	Recruiting	Metastatic Breast Cancer\|Recurrent Ovarian Carcinoma	University of Utah\|Novartis\|Acrotech Biopharma	May 3 2021	Phase 1
NCT04703920	Recruiting	Metastatic Breast Cancer\|Metastatic Castration-resistant Prostate Cancer\|Metastatic Ovarian Carcinoma	University of Michigan Rogel Cancer Center\|Pfizer\|Acrotech Biopharma Inc.	March 4 2021	Phase 1
NCT03772925	Active not recruiting	Recurrent Acute Myeloid Leukemia\|Recurrent Myelodysplastic Syndrome\|Refractory Acute Myeloid Leukemia\|Refractory Myelodysplastic Syndrome	National Cancer Institute (NCI)	June 20 2019	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Could you please give some suggestions for the use of it in vivo (i.p. injection)?

Answer:
For I.P. injection, it can be dissolved in 2% DMSO+30% PEG 300+ddH2O at 10 mg/ml clearly. When preparing the solution, please dissolve this compound in DMSO clearly first. Then add PEG, after they mixed well, then dilute with water. Hope this information is useful to you.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):